BCIQ Profiles

Company Profile ReportTarget Profile Report
0416 QT Deals
BioCentury & Getty Images


April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

Apr 17, 2021 | 12:57 AM GMT

The FTC has cleared the $39 billion takeout of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by AstraZeneca plc (LSE:AZN; NASDAQ:AZN), clearing a hurdle for the pharma at a time when biopharma M&A is under greater scrutiny by the agency. Regulatory clearances for the deal are pending in at least

Read the full 726 word article

How to gain access

Continue reading with a
two-week free trial.